Back

CRTX

1.65%
NEUTRAL

CRISM Therapeutics Wins Top Research Award

Why we think this is neutral

This RNS announcement is a general update on CRISM Therapeutics receiving an award, rather than a mandatory news type like a trading update or results. While the award recognition is positive, the RNS does not contain any financial or operational information that would significantly impact the company's performance or outlook.

Key Points

  • CRISM Therapeutics has been awarded the Drug Delivery and Translational Research Journal Outstanding Paper Award
  • The award recognizes the company's research on its ChemoSeed drug delivery technology for treating glioblastoma
  • The award provides third-party validation of the scientific merits and translational potential of ChemoSeed

Summary

The biotechnology company has been selected to receive a prestigious award for its research on a drug delivery technology for cancer treatments.

CRISM Therapeutics Corporation (AIM: CRTX), the innovative UK drug delivery company, has been selected to receive the Drug Delivery and Translational Research Journal Outstanding Paper Award by the Controlled Release Society. The award recognizes the most impactful and innovative original research article published in the journal over the past year, and highlights the scientific underpinnings and translational potential of CRISM's ChemoSeed technology for treating glioblastoma.

Key Dates

July 2025
CRS Annual Meeting where the award will be formally presented
Q2 2025
CRISM expects to submit a clinical trial application for ChemoSeed glioblastoma
GENERAL UPDATE